Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)
Status:
Completed
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
East Asian patients will be required optimal dose of newer P2Y12 inhibitors (prasugrel or
ticagrelor) to determine the safer treatment and better outcome. Whether lower dose of these
regimens are more adequate for clinical practice in Korea is unclear. Therefore, the
investigators aim to evaluate efficacy and safety of half dose of new oral P2Y12 inhibitors
in Korean patients with acute coronary syndrome (ACS) undergoing percutaneous coronary
intervention (PCI).